Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. Leuprolide Acetate injections will be manufactured at the Company's oncology injectable manufacturing facility at SEZ1, Ahmedabad ('ALIDAC').

Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept-2025).

The group now has 427 approvals and has so far filed 487* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 943.95 as compared to the previous close of Rs. 944.20. The total number of shares traded during the day was 25664 in over 1765 trades.

The stock hit an intraday high of Rs. 952.60 and intraday low of 939.65. The net turnover during the day was Rs. 24279502.00.

(*As on 30-Sept-25)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA FinalApproval LeuprolideAcetateInjection